Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754 - CISMeF
Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754NCIt concept
Preferred Label : Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754;
NCIt synonyms : Autologous Anti-STEAP2 CAR T Cells AZD0754; Autologous dnTGF-BRII-armored STEAP2-targeted CAR-T Cells AZD0754;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express
a chimeric antigen receptor (CAR) specific for the metalloreductase six-transmembrane
epithelial antigen of prostate-2 (STEAP2; STAMP1) and the dominant negative (dn) form
of transforming growth factor-beta (TGF-beta; TGFb) receptor 2 (dnTGF-BRII; dnTGFbR2),
with potential immunomodulating and antineoplastic activities. Upon reintroduction
into the patient, autologous dnTGF-BRII-armored anti-STEAP2 CAR T-cells AZD0754 are
directed to and induce selective toxicity in STEAP2-expressing tumor cells. STEAP2
is a cell surface antigen overexpressed in prostate cancer with limited expression
in normal tissue. The inclusion of dnTGF-BRII blocks the signaling of the immunosuppressive
cytokine TGFb in the tumor microenvironment (TME) and makes the AZD0754 CAR T-cells
resistant to TGFb. TGFb negatively regulates T-cell proliferation and activation and
plays a key role in tumor immune suppression.;